Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of BRII-835 (VIR-2218) plus pegylated interferon alfa in chronic hepatitis B
CTR20232864Phase 2Completed
- Sponsor
- Brii Biosciences
- Start
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of elebsiran, pegylated interferon alpha in Chronic Hepatitis B (CHB), sponsored by Brii Biosciences. Started Nov 2023; status: completed.
02
Drugs
elebsiranpegylated interferon alpha
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20232864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232864.